0001209191-16-096717.txt : 20160209 0001209191-16-096717.hdr.sgml : 20160209 20160209161820 ACCESSION NUMBER: 0001209191-16-096717 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160205 FILED AS OF DATE: 20160209 DATE AS OF CHANGE: 20160209 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coughlin Timothy P CENTRAL INDEX KEY: 0001376043 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 161399912 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-02-05 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001376043 Coughlin Timothy P 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Financial Officer Restricted Stock Unit 2016-02-05 5 A 0 E 10200 0.00 A Common Stock 10200 10200 D Stock Option 35.99 2016-02-05 5 A 0 E 48500 0.00 A 2026-02-05 Common Stock 48500 48500 D Restricted Stock Unit 2016-02-05 5 A 0 E 20500 0.00 A 2020-02-05 Common Stock 20500 20500 D Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2017, February 5, 2018, February 5, 2019, and February 5, 2020. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2016 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine. /s/Darin Lippoldt, Attorney-In-Fact 2016-02-09